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Kishwar Musa,4 Emma Graham,2 Thorbjørn Gantzel,5 Gillian Slynn,3 Michael E. Weinblatt,6
Morten A. Karsdal,4 Christian S. Thudium,4 and Anne-C. Bay-Jensen4
Objective. Rheumatoid arthritis (RA) is a chronic
and degenerative autoimmune joint disease that leads to
disability, reduced quality of life, and increased mortality.
Although several synthetic and biologic disease-modifying
antirheumatic drugs are available, there is still a medical
need for novel drugs that control disease progression. As
only 10% of experimental drug candidates for treatment
of RA that enter phase I trials are eventually registered
by the Food and Drug Administration, there is an imme-
diate need for translational tools to facilitate early deci-
sion-making in drug development. In this study, we
aimed to determine if the inability of fostamatinib (a
small molecule inhibitor of Syk) to demonstrate sufficient
efficacy in phase III of a previous clinical study could
have been predicted earlier in the development process.
Methods. Biomarkers of bone, cartilage, and
interstitial matrix turnover (C-telopeptide of type I colla-
gen [CTX-I], matrix metalloproteinase–derived types I,
II, and III collagen neoepitopes [C1M, C2M, and C3M])
were measured in 450 serum samples from the Oral Syk
Inhibition in Rheumatoid Arthritis 1 study (OSKIRA-1,
a phase III clinical study of the efficacy of fostamatinib in
RA) at baseline and follow-up. Additionally, the same
biomarkers were subsequently measured in conditioned
media from osteoclast, cartilage, and synovial membrane
cultured with the active metabolite of fostamatinib, R406,
to assess the level of suppression induced by the drug.
Results. In OSKIRA-1 serum samples and osteo-
clast and cartilage cultures, fostamatinib suppressed the
levels of CTX-I and C2M. In OSKIRA-1 serum samples
and synovial membrane cultures, fostamatinib did not
mediate any clinical or preclinical effect on either C1M
or C3M, which have previously been associated with dis-
ease response and efficacy.
Conclusion. These data demonstrate that trans-
lational biomarkers are a potential tool for early assess-
ment and decision-making in drug development for RA
treatment.
Rheumatoid arthritis (RA) is a chronic autoim-
mune disease estimated to affect 1.3 million adults in the
US (1). The first-line disease-modifying antirheumatic
drug (DMARD) for RA treatment is usually methotrex-
ate (MTX), which is often combined with conventional or
biologic DMARDs as second-line therapy (2,3). How-
ever, as some patients do not respond sufficiently to either
therapy, there is a need for drugs with alternative mecha-
nisms of action. Despite significant efforts, only 10% of
RA drugs that enter phase I clinical trials are likely to be
approved by the Food and Drug Administration (4,5).
Syk is a nonreceptor tyrosine kinase and is con-
sidered a possible target for RA treatment due to its
diverse biologic roles within inflammatory signaling,
cellular adhesion, pathogen recognition, bone meta-
bolism, tissue damage, and vascular effects (6,7). It is
expressed by hematopoietic cells including T and B
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lymphocytes, neutrophils, macrophages, and mast cells,
where it is involved with intracellular signaling related
to classic immunoreceptors (8). In addition, Syk is
expressed by cells found in joint tissues (bone, cartilage,
and synovium), where it is involved in downstream tumor
necrosis factor a (TNF) receptor signaling (9–11). Fosta-
matinib is a small-molecule inhibitor of Syk, and has been
tested as a potential novel DMARD for RA therapy.
In the Oral Syk Inhibition in Rheumatoid Arthri-
tis 1 study (OSKIRA-1), both patient groups treated with
fostamatinib exhibited statistically significant responses,
meeting the American College of Rheumatology criteria
for 20% improvement (ACR20) (12) at week 24 in
comparison to placebo; however, no effect on the pro-
gression of structural damage relative to placebo was
observed. The totality of the OSKIRA phase III program
indicated that the profile of this molecule was insuffi-
cient to warrant further development for RA (13,14). As
phase III clinical programs require considerable invest-
ment from patients, physicians, and sponsors, our goal in
the present investigation was to determine whether the
lack of structural efficacy in the fostamatinib OSKIRA-1
study could have been predicted earlier in the clinical
development process. If translational preclinical models
are able to reveal clinically relevant biomarker effects,
an early “go-or-no-go” decision would contribute to
improved success rates in the approval of novel drugs.
Biomarkers are increasingly being used to inform
clinicians regarding drug development decisions and
understanding of modes of action (15,16). Serologic
biomarkers can be used to help elucidate the effects of a
drug through preclinical models, as well as in clinical
studies (17). This presents an opportunity to identify
translational biomarkers in preclinical models of disease-
relevant target tissues or cell types, and translate the
effect into clinical studies and guide decision-making
during the drug development process.
Biomarkers of joint tissue turnover have been
used successfully to support and improve the under-
standing of clinical modes of action in RA (18). They are
considered to include 3 main classes: bone, cartilage, and
synovial inflammation. Bone resorption can be assessed
with C-telopeptide of type I collagen (CTX-I), a type I
collagen fragment generated by the main osteoclast pro-
tease cathepsin K (19,20). Bone formation can be
assessed with osteocalcin and N-terminal type I procolla-
gen propeptide (PINP). Osteocalcin is produced by
mature bone-forming osteoblasts, and PINP is released
upon incorporation of type I procollagen into mature
collagen (21,22). Matrix metalloproteinase (MMP)
degradation of type II collagen can be assessed with the
MMP-derived type II collagen neoepitope C2M (a
measure of cartilage degradation), as type II collagen is
predominantly found in cartilage (23,24). Finally, synovi-
tis can be assessed with total MMP-3 and acMMP-3, a
biomarker for active MMP-3 (25,26).
The connective tissue of the joint contains mainly
types I and III collagen (27,28). During joint inflamma-
tion, MMPs are increased, leading to increased degrada-
tion of extracellular matrix (ECM) components (29).
C1M and C3M are neoepitopes of MMP-2 and MMP-9–
degraded types I and III collagen, respectively. They serve
as biomarkers of interstitial membrane inflammation
(30,31). We have previously shown that C1M and C3M
are up-regulated in RA, osteoarthritis (OA), spondy-
loarthritis, and ex vivo in synovial membrane explants in
response to TNF (24,32–36). Importantly for the context
of this study, C1M has been shown to be prognostic for
disease progression in RA (33) and C1M and C3M levels
are correlated with disease activity (37,38), emphasizing
the significance of interstitial tissue inflammation for pro-
gression of disease. Acute systemic inflammation is esti-
mated using levels of C-reactive protein (CRP) and of
interleukin-6 (IL-6), a proinflammatory cytokine that cor-
relates with clinical disease activity in RA; chronic tissue
inflammation can be assessed with the neoepitope of
MMP-degraded CRP, CRPM (37,39,40).
Efficacious therapies such as tocilizumab (TCZ),
etanercept, MTX, adalimumab, and tofacitinib positively
modulate biomarkers of joint tissue turnover in RA and
ankylosing spondylitis (18,24,37,38,41). Therefore, we
tested whether the lack of efficacy of fostamatinib on
structural end points in the OSKIRA-1 phase III study
could have been predicted by the translation of biomarkers
of joint tissue turnover, measured in preclinical models.
PATIENTS AND METHODS
Study design. This study was undertaken to investigate
whether a translational model using serum-based biomarkers in
ex vivo and in vitro cultures could have predicted the insuffi-
cient clinical effect of fostamatinib on joint structure. In order
to investigate this, the clinical data from the OSKIRA-1 study
of fostamatinib in combination with MTX (13), a phase III,
multicenter, randomized, double-blind, placebo-controlled,
parallel-group study of RA patients whose illness did not ade-
quately respond to MTX therapy, were used. In vitro human
osteoclasts and ex vivo cultures of bovine cartilage and human
synovium were used to test the effect of the active metabolite
of fostamatinib, R406, on 4 biomarkers of ECM degradation
that were also measured in OSKIRA-1.
OSKIRA-1 was carried out in full accordance with the
principles of the Declaration of Helsinki and with the laws and
regulations of the countries in which the research was con-
ducted (which include Argentina, Australia, Belgium, Brazil,
Chile, Estonia, France, Hungary, India, Mexico, Peru, Poland,
Slovakia, Ukraine, the UK, and the US). All patients
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provided written informed consent, and the trials were
approved by all relevant institutional ethics committees or
review bodies and were conducted in accordance with the
principles of Good Clinical Practice and the AstraZeneca
Policy on Bioethics (https://www.astrazeneca.com/content/da
m/az/PDF/Bioethics_policy.pdf). Briefly, the OSKIRA-1 study
compared 2 patient cohorts (groups A and B) who were
receiving different dosing regimens of fostamatinib with a
placebo group. The study was placebo-controlled for the ini-
tial 24-week period, and all study patients continued to
receive MTX therapy. For the 24-week period, group A
received 100 mg fostamatinib twice daily in combination
with MTX and group B received 100 mg fostamatinib twice
daily in combination with MTX for the first 4 weeks, fol-
lowed by 150 mg fostamatinib once-daily maintenance in
combination with MTX; the placebo group received MTX
only. Placebo-treated patients who did not achieve a satis-
factory response (improvement in disease activity according
to the ACR20) by week 12 were able to transfer to active
treatment. Optional consent for serum collection at baseline
and week 24 was obtained from a subset of patients and
used for biomarker analysis. None of the placebo-treated
patients who were included in the biomarker analysis had
transferred to active treatment.
The statistical analysis plan was defined prior to data-
base lock and included an analysis of 9 exploratory biomarkers,
including assessment of bone balance (CTX-I:osteocalcin ratio).
Changes in biomarker levels and bone balance from baseline to
week 24 were assessed in each treatment group, and changes in
the active treatment groups were compared with those in the
placebo group. The biomarker analyses were based on those
patients in the full analysis set who consented to optional bio-
marker sampling and had evaluable data available at baseline
and at week 24.
Human osteoclast cultures.Human osteoclasts were gen-
erated from CD14+ monocytes isolated from peripheral blood,
as described previously (42). Briefly, CD14+ cells were isolated
from human super buffy coats received from the local hospital,
using CD14-coated Dynabeads M-450 (catalog no. 111.49D;
Invitrogen). The CD14+ cells were then cultured in a-minimum
essential medium (a-MEM) (catalog no. 041-94723M; Gibco)
with 1% penicillin/streptomycin (catalog no. P4333; Sigma-
Aldrich), thymidine (catalog no. A2265; AppliChem), 10% fetal
calf serum (FCS), and 25 ng/ml of macrophage colony-stimulat-
ing factor (M-CSF) (catalog no. 216-MC; R&D Systems) for the
first 3–4 days. Thereafter, the media were modified to a-MEM
containing penicillin/streptomycin, thymidine, 10% FCS, 25 ng/
ml M-CSF, and 25 ng/ml RANKL (catalog no. 390-TN; R&D Sys-
tems) and were incubated for 10–12 days for osteoclastogenesis,
changing every 2–3 days.
Resorption was assessed by seeding 25,000 mature osteo-
clasts per bovine bone slice 2 hours prior to the start of the exper-
iment. The mature osteoclasts were treated with DMSO as a
negative control, 100 nM diphyllin as a positive control inhibitor,
and R406 (catalog no. HY-12067; MedChem) at 9 lM, down to
0.3 lM in a 3-fold dilution. Three wells containing bone slices
without cells were included as a background control. The me-
dium was changed on day 3, and resorption stopped on day 6.
The conditioned media from day 6 were stored at –20°C until
measurements of Ca2+ and CTX-I were obtained. Metabolic
activity was assessed with alamarBlue (catalog no. DAL1100;
Invitrogen) on day 6. Briefly, the osteoclasts were incubated with
10% alamarBlue in a-MEM containing penicillin/streptomycin,
thymidine, 10% FCS, 25 ng/ml M-CSF, and 25 ng/ml RANKL for
3 hours. Fluorescence was then measured at 540 nm excitation
and 590 nm emission on a SpectraMax (Molecular Devices).
Explant cultures. Intact knees from cows ages 1–2 years
were used to make full-depth cartilage explants. The cow knees
were retrieved from the local butcher (Harald Hansens) at a max-
imum of 24 hours postmortem. The full-depth cartilage explants
were punched from the lateral and medial femoral condyle with
a biopsy puncher of 3 mm (catalog no. MTP-33-32; Scandidact)
and released from the bone with a scalpel. They were placed in
96-well plates with Dulbecco’s modified Eagle’s medium
(DMEM)/F-12 (catalog no. 31331-093; Invitrogen) with 1% peni-
cillin/streptomycin, 24 hours prior to treatment. The full-depth
cartilage explants were cultured for 3 weeks with DMEM/F-12,
1% penicillin/streptomycin, and DMSO, with 10 ng/ml oncostatin
M (OSM), 2 ng/ml TNF, and DMSO, or with OSM and TNF
together with 2.5 lM, 0.625 lM, or 0.156 lM R406.
Synovial membrane explants were made using synovial
membrane biopsy specimens obtained from OA patients under-
going total knee replacement at Gentofte University Hospital.
All patients provided written informed consent, and the Danish
scientific ethical commission approved the trials (H-D-2007-
0084). Fat was removed from the synovial membrane specimens,
which were cut into explants of 30 mg (5 mg). The synovial
membrane explants were incubated overnight in DMEM/F-12
and 1% penicillin/streptomycin prior to treatment start. They
were cultured for 14 days with DMEM/F-12, 1% penicillin/strep-
tomycin, and DMSO, with 10 ng/ml TNF and DMSO, or with
10 ng/ml TNF and 5 lM, 0.5 lM, or 0.05 lM R406 (6 patients)
or 10 ng/ml TNF and 5 lM, 2.5 lM, 1.25 lM, or 0.63 lM R406 (5
patients). Between 1 and 4 technical replicates were included per
patient and a total of 11 patients were used to test R406. The
conditioned media were changed 3 times per week with the addi-
tion of fresh treatment for all explant cultures and were stored at
–20°C until measurement of C2M, C1M, C3M, and acMMP-3.
Biochemical biomarker assays and calcium measure-
ments. Assays for osteocalcin, PINP, and CTX-I were conducted
on serum acquired from patients at baseline and week 24. CTX-I,
PINP, and osteocalcin in serum were measured individually with
an Elecsys 2010 analyzer (Roche Diagnostics) using CrossLaps,
total PINP, and N-terminal midfragment, respectively. Condi-
tioned media CTX-I was measured with CrossLaps for Culture
CTX-I (catalog no. AC07F1; IDS) according to the instructions
of the manufacturer.
Quantitative competitive enzyme-linked immunosorbent
assays were used to measure the biomarkers C1M, C2M, and
C3M in the OSKIRA-1 study at baseline and week 24 and in
conditioned media from cartilage or synovium ex vivo cultures as
described previously (23,30,31,39). Briefly, streptavidin-coated
96-well microtiter plates were coated with a biotinylated peptide
specific for each biomarker. After washing to eliminate unbound
biotinylated peptide, standards, controls, samples, and horserad-
ish peroxidase (HRP)–conjugated monoclonal antibodies speci-
fic for each biomarker were added to the assay plates. Following
a wash to remove unbound HRP-conjugated antibody, the sub-
strate solution 3,30,5,50-tetramethylbenzidine was added. Color
development was terminated by adding sulfuric acid, and the
intensity of the color was measured with SpectraMax (Molecular
Devices). The concentration of total calcium was measured in
culture supernatants after resorption using a colorimetric assay
and a Hitachi 912 Automatic Analyzer (Roche Diagnostics).
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Statistical analysis. In the OSKIRA-1 study, the analysis
methods were determined a priori and were recorded in an
exploratory analysis plan. As the biomarker data were not nor-
mally distributed, they were log transformed prior to analysis.
The mean change was derived on the original scale. The log-
transformed data were analyzed using an analysis of covariance
model on the change from baseline, including terms for baseline
as a continuous covariate and treatment and country as factors.
The results were displayed as back-transformed ratios to base-
line and ratios between treatments. Due to an insufficient
amount of material for biomarker measurements, CTX-I was
measured in 447 patients, osteocalcin in 448 patients, PINP in
447 patients, C1M in 448 patients, IL-6 in 445 patients, and
MMP-3 in 448 patients. The missing values were not imputed in
the statistical analysis.
For the preclinical study, the biomarker levels from the
ex vivo data were plotted as a function of time of culture, and
the total release of biomarkers was quantified by calculating the
area under the curve (AUC) using GraphPad Prism version 6.07.
CTX-I, Ca2+, and metabolic activity in the osteoclast culture
were measured on day 6. The AUC values, CTX-I, Ca2+, and
metabolic activity were analyzed by Kruskal-Wallis test followed
by Dunn’s multiple comparison test, performed with GraphPad
Prism version 6.07. For all biomarker measurements, any values
below the lower limit of the measurement range were imputed
as the lower limit of the measurement range.
RESULTS
Patient population. In the OSKIRA-1 study, 923
patients were randomized to receive fostamatinib (group A,
n = 311; group B, n = 306) or placebo (n = 306), all of whom
had also received MTX (13). Of these patients, 450 had
provided consent for serum collection and had evaluable
samples at baseline and at week 24 (group A, n = 164;
group B, n = 153; placebo, n = 133), representing 43–53%
of patients from each treatment arm. This subset of patients
was used for biomarker analysis, although 5 of the 450 sam-
ples did not contain sufficient material to allow measure-
ment of all biomarkers. Baseline clinical and demographic
data for this subset of patients for biomarker analysis sug-
gest that these patients were a reasonable representation of
the overall intent-to-treat population (13). Demographic
characteristics of the patients in the OSKIRA-1 study are
summarized in Supplementary Table 1 (available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.40527/abstract).
Decrease in serum levels of bone biomarkers after
fostamatinib treatment. In the OSKIRA-1 study, there
was a 30% decrease in CTX-I from baseline to week 24
in group A and a 26% decrease in group B, as well as
a small decrease in the placebo group (3%) (Fig-
ure 1A). Compared with patients who had received pla-
cebo, group A showed a 28% decrease (P < 0.001) and
group B showed a 23% decrease (P < 0.001). Similarly,
osteocalcin levels from baseline to week 24 decreased
by 20% in group A, by 16% in group B, and by 2% in the
placebo group (Figure 1B). Compared with the placebo
group, osteocalcin levels were decreased by 18% in group
A (P < 0.001) and by 14% in group B (P < 0.001). The
CTX-I:osteocalcin ratio is considered to be the bone bal-
ance, which can be used to assess the net gain or loss of
bone (43). Despite an overall suppression of bone turn-
over, the bone balance favored net bone formation (os-
teocalcin) over bone resorption (CTX-I) in groups A and
B (Figure 1C). As an alternate marker of bone formation
and consistent with the reduction in osteocalcin levels, the
geometric mean levels of PINP decreased by 24% and
18% from baseline to week 24 in groups A and B, respec-
tively (Figure 1D). Compared with geometric mean levels
of PINP in the placebo group (1%), levels in groups A
and B were significantly decreased (by 24% and 19%,
respectively; P < 0.001 for both).
Changes in joint tissue degradation biomarker
levels following fostamatinib treatment. Changes in the
levels of joint tissue degradation biomarkers from baseline
to week 24 are summarized in Figure 2. There were no sta-
tistically significant differences in C1M or C3M in the fosta-
matinib treatment groups versus the placebo group
(Figures 2A and C). C2M levels decreased from baseline by
Figure 1. Reduction of bone biomarkers and bone balance by fostamatinib. The ratios of the levels of C-telopeptide of type I collagen (CTX-I)
(A), osteocalcin (B), and N-terminal type I procollagen propeptide (PINP) (D) and the CTX-I:osteocalcin ratio (C) at 24 weeks compared to base-
line are shown. Patients in group A received 100 mg fostamatinib twice daily in combination with methotrexate (MTX), group B began with
100 mg fostamatinib twice daily in combination with MTX for the first 4 weeks, followed by 150 mg fostamatinib once daily maintenance in
combination with MTX, and the placebo-treated patients received MTX only. Values are the mean  SEM. * = P = < 0.05; ** = P = < 0.01;
*** = P = < 0.001, versus baseline.
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5% in group A and 2% in group B, while a small increase
was observed in the placebo group (3%) (Figure 2B). The
difference from placebo was statistically significant only in
group A (8%; P = 0.027). Three additional biomarkers—
CRPM, IL-6, and total MMP-3—were also measured.
Fostamatinib had no effect on CRPM; however, lower
levels of IL-6 were demonstrated in group A, and levels of
total MMP-3 decreased in both groups A and B. (see Sup-
plementary Figure 1, available on the Arthritis & Rheumatol-
ogy web site at http://onlinelibrary.wiley.com/doi/10.1002/art.
40527/abstract).
Back-translation of the effect of fostamatinib on
biomarker release ex vivo. Fostamatinib is an oral pro-
drug, which is rapidly converted to the active metabolite,
R406. The effect of R406 on joint tissue turnover was ret-
rospectively investigated in in vitro and ex vivo models of
bone, cartilage, and synovial tissue after the OSKIRA-1
study was conducted.
Diphyllin, a control for inhibition of bone resorp-
tion, significantly reduced resorption by mature human
osteoclasts on bovine bone slices, as compared with
DMSO. This was measured with Ca2+ and CTX-I release
(P = 0.002) (Figures 3A and B). Similarly, R406 decreased
the release of Ca2+ and CTX-I into the conditioned
media in a dose-dependent manner, with significance at 1
lM (P = 0.037 and P = 0.026 for Ca2+ and CTX-I, respec-
tively) (Figures 3A and B). The decrease of Ca2+ and
CTX-I in response to R406 was accompanied by a dose-
dependent decrease in metabolic activity. At 3 lM, R406
significantly decreased metabolic activity (P = 0.009).
Diphyllin did not affect osteoclast metabolic activity
(Figure 3C).
Bovine cartilage explants treated with OSM and
TNF released C2M in the late stage of the culture
period (days 14–21) (Figure 4A). The total release of
C2M was significantly higher in bovine cartilage explants
treated with OSM and TNF compared to that observed
without the treatment (P = 0.008). R406 inhibited total
C2M release in a dose-dependent manner, with signifi-
cance at 1.25 lM (P < 0.001) (Figure 4B).
Figure 2. Joint tissue degradation. The ratios of the levels of matrix metalloproteinase–derived type I collagen neoepitope (C1M) (A), C2M (B), and
C3M (C) at 24 weeks compared to baseline are shown. Patients in group A received 100 mg fostamatinib twice daily in combination with methotrexate
(MTX), group B began with 100 mg fostamatinib twice daily in combination with MTX for the first 4 weeks, followed by 150 mg fostamatinib once
daily maintenance in combination with MTX, and the placebo-treated patients received MTX only. Values are the mean  SEM. * = P = < 0.05.
Figure 3. Effect of R406 on bone resorption and osteoclast metabolic activity. Bone resorption was measured in conditioned media from mature
human osteoclasts cultured in bovine bone slices for 6 days, and levels of Ca2+ (A) and C-telopeptide of type I collagen (CTX-I) (B) were
measured. Dotted lines represent the value of conditioned media from wells with bone slices but no osteoclasts. Metabolic activity of the human
osteoclasts on the last day of culture was measured with alamarBlue (C). Bars show the mean  SEM from 6 replicates. * = P = < 0.05;
** = P = < 0.01; *** = P = < 0.001; **** = P = < 0.0001, versus DMSO treatment. NS = not significant.
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TNF increased the release of C1M and C3M
from human synovial membrane explants, with a peak at
approximately days 5–10 of the culture period (Fig-
ures 5A and B), and the total release of C1M and C3M
was significantly increased by TNF compared to that
observed without TNF treatment (P = 0.001 and P <
0.001, respectively) (Figures 5C and D). R406 inhibited
the release of C1M and C3M in a dose-dependent man-
ner, but the degree of inhibition was significant only at
5 lM (P = 0.030 and P = 0.046 for C1M and C3M,
respectively) (Figure 5C). Levels of acMMP-3 in the
synovial membrane explants increased from day 5 in
response to TNF, resulting in a significant total release
of acMMP-3 (P = 0.005) compared to that observed
without TNF treatment acMMP-3 (see Supplementary
Figures 2A and B, available at http://onlinelibrary.wiley.
com/doi/10.1002/art.40527/abstract). R406 tended to de-
crease acMMP-3 release at 5 lM (P = 0.051).
DISCUSSION
It was recently found that fostamatinib, a small
molecule inhibitor of Syk, did not meet the coprimary
structural end point of the OSKIRA-1 phase III study
(13), and further development for its usage for treatment
of RA was consequently discontinued. This was despite
the fact that fostamatinib had shown a promising effect on
structure in preclinical trials using animal models (44).
Fostamatinib thereby joined the large number of potential
RA therapeutic drugs that enter clinical development but
are never approved for treatment of RA (4,5). There is a
need for novel translational tools to identify an RA treat-
ment that can provide patients with sufficient joint protec-
tion before they are exposed to a drug in a phase III study.
In the present study, we investigated findings from the
OSKIRA-1 study. Utilizing translational biomarkers of
joint tissue turnover, we found inhibition of bone resorp-
tion, minimal inhibition of cartilage degradation, and no
effect on inflammatory interstitial matrix degradation in
clinical and preclinical models of the 3 main joint tissues.
The role of Syk in cartilage turnover is not well
described. Syk is involved in stimulation of OA chondro-
cytes by basic calcium phosphate crystals (10), indicating
that chondrocytes do express functional Syk. C2M was
used to quantify cartilage degradation, as serum C2M
has been shown to predict early response in patients
receiving treatment with TCZ and has recently been
shown to predict development of erosive disease in
patients with early RA (18,45,46). Ex vivo, R406 inhibited
TNF- and OSM-stimulated C2M release.
Figure 4. R406 inhibits the release of matrix metalloproteinase (MMP)–derived type II collagen neoepitope (C2M) ex vivo. Cartilage MMP
degradation was quantified by measurement of C2M levels in conditioned media from bovine cartilage explants (A). C2M is plotted as the fold
change versus without treatment (w/o) (baseline) over time after treatment start. Area under the curve (AUC) for C2M release over 21 days was
determined (B). Bars show the mean  SEM from 12 replicates in 2 experiments. ** = P = < 0.01; *** = P = < 0.001; **** = P = < 0.0001,
versus baseline. OSM = oncostatin M; TNF = tumor necrosis factor.
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This inhibition translated to the OSKIRA-1 study,
in which serum C2M levels were significantly decreased in
patient group A compared to the placebo group. However,
minimal effect on clinical cartilage erosion was observed in
the OSKIRA-1 study (13). This might be due to the con-
centration of R406 in the cartilage of the patients. Aque-
ous fostamatinib (160 mg, twice daily) reaches a steady
state at ~1 lM R406 in plasma, and a single dose of 75 mg
fostamatinib as a tablet reaches a maximum concentration
of 0.8–1.3 lM (47). Group A patients in the OSKIRA-1
study would have had ~1 lM R406 in circulation. How-
ever, as cartilage is an avascular tissue, the concentration
of R406 in cartilage is likely to be <1 lM, and possibly in
the range where R406 has limited inhibitory effect on car-
tilage degradation. This correlates with the finding that
group A had 5% lower C2M levels compared to the pla-
cebo group, indicating some inhibition of cartilage degra-
dation (although too little to have a clinical effect on
cartilage erosion). We have previously shown that a 12%
decrease in C2M levels corresponds with efficacious clini-
cal results of TCZ treatment (24).
Inflammatory interstitial tissue degradation can be
monitored by C1M and C3M levels (both biomarkers that
are up-regulated in RA) and correlated with inflamma-
tory status in OA patients (32,34,37,38,48). C1M and
C3M were included in the prospective analysis plan for
OSKIRA-1, since C1M has been shown to be prognos-
tic of RA progression, and both C1M and C3M have
been shown to be associated with efficacy of treatment
(18,33,38,46). In the present study, we did not see any
effect of fostamatinib on C1M or C3M concentrations in
any of the treatment groups. Ex vivo, we found that R406
at 5 lM decreased C1M and C3M levels. However, at a
clinically relevant concentration (~1 lM), it had no effect
on TNF-stimulated C1M or C3M release. In the Tocilizu-
mab Safety and the Prevention of Structural Joint Dam-
age study, TCZ decreased C1M levels by 20–40%
compared to placebo at the 2 doses tested, and C3M
Figure 5. R406 inhibits ex vivo release of joint tissue biomarkers only at high concentrations. MMP degradation of type I collagen (A) and type
III collagen (B) in conditioned media from human synovial explants was quantified with MMP-derived C1M and C3M, respectively, and plotted as
ng/ml released over time. AUC for biomarker release of C1M (C) and C3M (D) from human synovial explants over 14 days was determined. Bars
show the mean  SEM from 6 patients. * = P = < 0.05; *** = P = ≤ 0.001, versus treatment with TNF only. See Figure 4 for definitions.
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levels by ~25% at the highest dose compared to placebo
(24,33). Additionally, in a study of a Japanese population,
we showed that MTX and TCZ reduced C1M concentra-
tions, and MTX, TCZ, adalimumab, and tofacitinib
reduced C3M concentrations, to levels comparable to
those in healthy subjects (38). C1M and C3M can be con-
sidered to be effective putative biomarkers of joint struc-
ture protection, and therefore we would expect an
efficacious treatment to decrease both. However, as no
effect of fostamatinib on either C1M or C3M was
observed in OSKIRA-1 serum samples or ex vivo at rele-
vant concentrations, fostamatinib would not be expected
to have an efficacious protective effect on joint structure.
It is well-documented that in bone, Syk plays an
important role in osteoclast function through osteoclasto-
genesis and organization of the cytoskeleton (11,49,50).
Additionally, there are data indicating that Syk is involved
in osteoblast differentiation (51). Consistent with these
findings, our study demonstrates that the inhibition of Syk
by fostamatinib significantly decreased the release of
CTX-I both in vitro and clinically. In vitro, bone resorp-
tion (measured with both CTX-I and Ca2+) by mature
osteoclasts was significantly reduced in a dose-dependent
manner by the active metabolite of fostamatinib, R406.
Additionally, R406 decreased the metabolic activity of the
osteoclasts. This observation has not been previously
reported, and might explain the in vitro reduced bone
resorption observed in the present study. Consistent with
human osteoclast data, CTX-I was decreased by 23–31%
in both treatment groups compared to the placebo group
in the OSKIRA-1 study. This effect is comparable to both
the effect of TCZ (decreasing CTX-I to ~25%) and the
range of CTX-I reduction previously demonstrated to
improve bone quality in phase III clinical studies of osteo-
porosis (43,52,53).
Treatment with fostamatinib also reduced bone for-
mation as measured with osteocalcin and PINP. This is
most likely due to the strong coupling between bone
resorption and bone formation, in which a decrease
in bone formation is observed secondarily to a decrease in
bone resorption (54). However, the resultant bone balance
(CTX-I:osteocalcin ratio) decreased significantly in the
fostamatinib treatment groups (by 10–12% compared to
the placebo group) and favored a net gain in bone.
We have demonstrated back-translation of the
effect of fostamatinib on joint tissue remodeling, includ-
ing decreased levels of biomarkers of bone resorption
and, in part, cartilage degradation, and reproduced the
lack of effect on biomarkers of inflammatory interstitial
matrix degradation. Use of similar models as decision
tools in early drug development would enable earlier go/
no-go decision points in RA drug development.
Our study had some limitations. Biomarker analy-
ses were derived from patients with both baseline and
week 24 biomarker data available, rather than from the
complete set of patients who had consented to provide
samples for biomarker analysis. This analysis set there-
fore comprised patients with a generally more favorable
outcome of their randomized treatment. In the
OSKIRA-1 study, patients could transfer to a long-term
extension study to receive fostamatinib 100 mg twice
daily if they did not achieve a satisfactory response by
week 12. Potential bias may therefore have been intro-
duced into the biomarker analyses, given that a higher
proportion of patients who were treated with fostama-
tinib completed 24 weeks than those treated with pla-
cebo. Additionally, since the assessment of biomarkers in
the OSKIRA-1 study was an exploratory end point, the
study was not prospectively sized for the analyses of bio-
marker data and anticipated treatment effects, and might
therefore have been overpowered. Hence, caution
should be applied when interpreting statistical signifi-
cance of these biomarker analyses, as clinical significance
is not necessarily implied.
The tissue culture, species, and disease-dependent
differences between models and clinical measurements
should also be taken into account when interpreting the
data. Generally, the ex vivo models focus on single tissues.
Thus, they do not take into account delivery of com-
pounds. Our in vitro and ex vivo models were conducted
after OSKIRA-1 was completed, and therefore we do not
know how our data might have influenced the clinical
study design.
In conclusion, it is recommended for future devel-
opment of drugs for the treatment of RA, the value of
exploratory biomarker analyses should be considered as
part of phase II clinical studies. In addition, the potential
impact of these findings should be fully considered in
decision-making for later-stage clinical development.
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